118 related articles for article (PubMed ID: 28951423)
1. Potential contribution of tumor-associated slan
Lonardi S; Licini S; Micheletti A; Finotti G; Vermi W; Cassatella MA
J Leukoc Biol; 2018 Mar; 103(3):559-564. PubMed ID: 28951423
[TBL] [Abstract][Full Text] [Related]
2. Macrophage Susceptibility to Emactuzumab (RG7155) Treatment.
Pradel LP; Ooi CH; Romagnoli S; Cannarile MA; Sade H; Rüttinger D; Ries CH
Mol Cancer Ther; 2016 Dec; 15(12):3077-3086. PubMed ID: 27582524
[TBL] [Abstract][Full Text] [Related]
3. slan
Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
[TBL] [Abstract][Full Text] [Related]
4. A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells.
Haegel H; Thioudellet C; Hallet R; Geist M; Menguy T; Le Pogam F; Marchand JB; Toh ML; Duong V; Calcei A; Settelen N; Preville X; Hennequi M; Grellier B; Ancian P; Rissanen J; Clayette P; Guillen C; Rooke R; Bonnefoy JY
MAbs; 2013; 5(5):736-47. PubMed ID: 23924795
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
Machiels JP; Gomez-Roca C; Michot JM; Zamarin D; Mitchell T; Catala G; Eberst L; Jacob W; Jegg AM; Cannarile MA; Watson C; Babitzki G; Korski K; Klaman I; Teixeira P; Hoves S; Ries C; Meneses-Lorente G; Michielin F; Christen R; Rüttinger D; Weisser M; Delord JP; Cassier P
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33097612
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Ries CH; Cannarile MA; Hoves S; Benz J; Wartha K; Runza V; Rey-Giraud F; Pradel LP; Feuerhake F; Klaman I; Jones T; Jucknischke U; Scheiblich S; Kaluza K; Gorr IH; Walz A; Abiraj K; Cassier PA; Sica A; Gomez-Roca C; de Visser KE; Italiano A; Le Tourneau C; Delord JP; Levitsky H; Blay JY; Rüttinger D
Cancer Cell; 2014 Jun; 25(6):846-59. PubMed ID: 24898549
[TBL] [Abstract][Full Text] [Related]
7. Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis.
Toh ML; Bonnefoy JY; Accart N; Cochin S; Pohle S; Haegel H; De Meyer M; Zemmour C; Preville X; Guillen C; Thioudellet C; Ancian P; Lux A; Sehnert B; Nimmerjahn F; Voll RE; Schett G
Arthritis Rheumatol; 2014 Nov; 66(11):2989-3000. PubMed ID: 24623505
[TBL] [Abstract][Full Text] [Related]
8. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
[TBL] [Abstract][Full Text] [Related]
9. slan-defined subsets of CD16-positive monocytes: impact of granulomatous inflammation and M-CSF receptor mutation.
Hofer TP; Zawada AM; Frankenberger M; Skokann K; Satzl AA; Gesierich W; Schuberth M; Levin J; Danek A; Rotter B; Heine GH; Ziegler-Heitbrock L
Blood; 2015 Dec; 126(24):2601-10. PubMed ID: 26443621
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Gomez-Roca CA; Italiano A; Le Tourneau C; Cassier PA; Toulmonde M; D'Angelo SP; Campone M; Weber KL; Loirat D; Cannarile MA; Jegg AM; Ries C; Christen R; Meneses-Lorente G; Jacob W; Klaman I; Ooi CH; Watson C; Wonde K; Reis B; Michielin F; Rüttinger D; Delord JP; Blay JY
Ann Oncol; 2019 Aug; 30(8):1381-1392. PubMed ID: 31114846
[TBL] [Abstract][Full Text] [Related]
11. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
Stafford JH; Hirai T; Deng L; Chernikova SB; Urata K; West BL; Brown JM
Neuro Oncol; 2016 Jun; 18(6):797-806. PubMed ID: 26538619
[TBL] [Abstract][Full Text] [Related]
12. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.
Valero JG; Matas-Céspedes A; Arenas F; Rodriguez V; Carreras J; Serrat N; Guerrero-Hernández M; Yahiaoui A; Balagué O; Martin S; Capdevila C; Hernández L; Magnano L; Rivas-Delgado A; Tannheimer S; Cid MC; Campo E; López-Guillermo A; Colomer D; Pérez-Galán P
Leukemia; 2021 Sep; 35(9):2635-2649. PubMed ID: 33731849
[TBL] [Abstract][Full Text] [Related]
13. The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor.
Swierczak A; Cook AD; Lenzo JC; Restall CM; Doherty JP; Anderson RL; Hamilton JA
Cancer Immunol Res; 2014 Aug; 2(8):765-76. PubMed ID: 25005824
[TBL] [Abstract][Full Text] [Related]
14. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.
Saung MT; Muth S; Ding D; Thomas DL; Blair AB; Tsujikawa T; Coussens L; Jaffee EM; Zheng L
J Immunother Cancer; 2018 Nov; 6(1):118. PubMed ID: 30424804
[TBL] [Abstract][Full Text] [Related]
15. The slan antigen identifies the prototypical non-classical CD16
Tamassia N; Bianchetto-Aguilera F; Gasperini S; Grimaldi A; Montaldo C; Calzetti F; Gardiman E; Signoretto I; Castellucci M; Barnaba V; Tripodi M; Cassatella MA
Front Immunol; 2023; 14():1287656. PubMed ID: 37965335
[TBL] [Abstract][Full Text] [Related]
16. Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes.
Webb MW; Sun J; Sheard MA; Liu WY; Wu HW; Jackson JR; Malvar J; Sposto R; Daniel D; Seeger RC
Int J Cancer; 2018 Sep; 143(6):1483-1493. PubMed ID: 29665011
[TBL] [Abstract][Full Text] [Related]
17. Muramyl dipeptide and mononuclear cell supernatant induce Langhans-type cells from human monocytes.
Mizuno K; Okamoto H; Horio T
J Leukoc Biol; 2001 Sep; 70(3):386-94. PubMed ID: 11527988
[TBL] [Abstract][Full Text] [Related]
18. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
[TBL] [Abstract][Full Text] [Related]
19. Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations.
Lohela M; Casbon AJ; Olow A; Bonham L; Branstetter D; Weng N; Smith J; Werb Z
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):E5086-95. PubMed ID: 25385645
[TBL] [Abstract][Full Text] [Related]
20. Anti-CSF-1 treatment is effective to prevent carcinoma invasion induced by monocyte-derived cells but scarcely by microglia.
Rietkötter E; Bleckmann A; Bayerlová M; Menck K; Chuang HN; Wenske B; Schwartz H; Erez N; Binder C; Hanisch UK; Pukrop T
Oncotarget; 2015 Jun; 6(17):15482-93. PubMed ID: 26098772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
